

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJHM1624

PASSWORD :

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 16:13:18 ON 02 JUL 2007

=> FILE REGISTRY
COST IN U.S. DOLLARS
SINCE FILE
ENTRY
TOTAL
SESSION
FULL ESTIMATED COST
0.21
0.21

FILE 'REGISTRY' ENTERED AT 16:13:28 ON 02 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 1 JUL 2007 HIGHEST RN 940612-32-8
DICTIONARY FILE UPDATES: 1 JUL 2007 HIGHEST RN 940612-32-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10564844a.str



chain nodes :

10 11 24 25 26 27 28 29 30

ring nodes :

1 2 3 4 5 6 7 8 9 12 13 14 15 16 17 18 19 20 21 22 23

chain bonds :

1-10 3-11 7-18 11-12 14-25 22-24 25-30 25-26 26-27 27-28 28-29

ring bonds :


1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 12-13 12-17 13-14 14-15 15-16
 16-17 18-19 18-23 19-20 20-21 21-22 22-23
 exact/norm bonds :
 3-11 5-7 6-9 7-8 7-18 8-9 11-12 25-30 25-26
 exact bonds :
 1-10 14-25 22-24 26-27 27-28 28-29
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17 18-19
 18-23 19-20 20-21 21-22 22-23

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
 11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
 20:Atom 21:Atom 22:Atom 23:Atom 24:CLASS 25:CLASS 26:CLASS 27:CLASS
 28:CLASS 29:CLASS 30:CLASS

L1 STRUCTURE UPLOADED

=> d 11
 L1 HAS NO ANSWERS
 L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11
 SAMPLE SEARCH INITIATED 16:13:51 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED 1 ITERATIONS 0 ANSWERS
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**

PROJECTED ITERATIONS: 1 TO 80
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1


=> s 11 full
FULL SEARCH INITIATED 16:13:54 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 7 TO ITERATE

100.0% PROCESSED 7 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

L3 1 SEA SSS FUL L1

=> d scan

L3 1 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, 3-[(3-(3-fluorophenyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl)amino]-N-(2-hydroxyethyl)- (9CI)
MF C19 H16 F N7 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
172.10	172.31

FILE 'CAPLUS' ENTERED AT 16:14:08 ON 02 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Jul 2007 VOL 147 ISS 2
FILE LAST UPDATED: 1 Jul 2007 (20070701/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13
L4 1 L3
=> d 14 ibib abs hitstr

ACCESSION NUMBER: 2005122890 CAPLUS

DOCUMENT NUMBER: 14219305

TITLE: Preparation of triazolopyrimidines as glycogen

synthase kinase 3 inhibitors

INVENTOR(S): Freyne, Eddy Jean Edgard; Love, Christopher John; Coeymans, Ludwig Paul; Vandermaesen, Nele; Buijnsters, Peter Jacobus Johannes Antonius; Willems, Marc; Embrechts, Werner Constant Johan

PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.

SOURCE: PCT Int. Appl., 124 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012307	A1	20050210	WO 2004-EP51455	20040712
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, T2, US, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DX, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
AU 2004260738	A1	20050210	AU 2004-260738	20040712
CA 2531333	A1	20050210	CA 2004-2531333	20040712
EP 16560292	A1	20060524	EP 2004-766189	20040712
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, NC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1823068	A	20060823	CN 2004-80020148	20040712
BR 2004012596	A	20060919	BR 2004-12596	20040712
US 2006205721	A1	20060914	US 2006-564844	20060113
NO 2006000678	A	20060210	NO 2006-678	20060210
PRIORITY APPLN. INFO.:			WO 2003-EP350310	A 20030716
			WO 2004-EP51455	W 20040712

OTHER SOURCE(S): CASREACT 142:219305; MARPAT 142:219305


GI



AB: The title compds. I (ring A = Ph, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl; R1 = H, aryl, formyl, etc.; X = a direct bond, $(\text{CH}_2)_n$ or $(\text{CH}_2)_m\text{X}1a$ (n = 1-4; m = 1-2; X1a = O, C(=O), NR5; X1b = a direct bond, alkyl); R2 = cycloalkyl, Ph, 4-7 membered monocyclic heterocycle containing at least one heteroatom, selected from O, S or N, benzoxazolyl, etc.; R3 = halo, OH, (un)substituted alkyl, alkenyl or alkynyl, etc.; R4 = H, halo, OH, (un)substituted alkyl, alkenyl, etc.; R5 = H, alkyl, alkenyl), useful for the prevention or the treatment of diseases mediated through GSK3, were prepared E.g., a 4-step synthesis of II which showed pIC_{50} of > 8 against GSK3 β and against GSK3 α , was given. The pharmaceutical composition comprising the compound I is disclosed.

IT: 840535-34-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses);
(preparation of triazolopyrimidines as glycogen synthase kinase 3 inhibitors)

RN: 840535-34-4 CAPLUS
CN: Benzanide, 3-[(3-(3-fluorophenyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl)amino]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file registry			
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION	
FULL ESTIMATED COST	5.74	178.05	
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION	
CA SUBSCRIBER PRICE	-0.78	-0.78	

FILE 'REGISTRY' ENTERED AT 16:14:46 ON 02 JUL 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 1 JUL 2007 HIGHEST RN 940612-32-8
 DICTIONARY FILE UPDATES: 1 JUL 2007 HIGHEST RN 940612-32-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
 Uploading C:\Program Files\Stnexp\Queries\10564844b.str



chain nodes :
10 11 19 21
ring nodes :
1 2 3 4 5 6 7 8 9 12 13 14 15 16 17
chain bonds :
1-10 3-11 7-19 11-12 11-21
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 12-13 12-17 13-14 14-15 15-16
16-17
exact/norm bonds :
3-11 5-7 6-9 7-8 7-19 8-9 11-12 11-21
exact bonds :
1-10
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17


G1: Cy, H, Ak, C

G2: H, C, Cb, Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 19:CLASS 21:CLASS

L5 STRUCTURE UPLOADED

=> d 15
L5 HAS NO ANSWERS
L5 STR



G1 Cy, H, Ak, C
G2 H, C, Cb, Ak

Structure attributes must be viewed using STN Express query preparation.


=> s 15
SAMPLE SEARCH INITIATED 16:15:14 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 132 TO ITERATE
100.0% PROCESSED 132 ITERATIONS 28 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1951 TO 3329
PROJECTED ANSWERS: 243 TO 877

L6 28 SEA SSS SAM L5

=> d scan


L6 28 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzeneacetamide, 3-(5-[(3-(5-oxazolyl)phenyl]amino)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI)
MF C21 H16 N8 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 28 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzoic acid, 2-(acetylamino)-5-[[3-[3-[(methoxyacetyl)amino]methyl]phenyl]amino]-1-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino)-, methyl ester (9CI)
MP C24 H24 N8 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s 15 full sss

FULL SEARCH INITIATED 16:17:44 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 2448 TO ITERATE

100.0% PROCESSED 2448 ITERATIONS

SEARCH TIME: 00.00.01

601 ANSWERS



L7 601 SEA SSS FUL L5

=> d scan

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 20061884440 CAPLUS
 DOCUMENT NUMBER: 1451293080
 TITLE: Preparation and GSK-3 modulation of 2,4,5-trisubstituted pyrimidine and bicyclic 2-aminopyrimidine derivatives
 INVENTOR(S): Sebo, Lubomir; Kahl, Jeffrey; Lum, Christopher; Pei, Yizhong; Pryor, Kent E.; Urban, Jan; Jones, Bryan; Sullivan, Robert
 PATENT ASSIGNEE(S): Kenis, Inc., USA
 SOURCE: PCT Int. Appl., 119pp.
 CODEN: PIKXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006091737	A1	20060831	WO 2006-US6447	20060223
W1	AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RU	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SB, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, HL, MR, NE, SN, TD, TG, BW, GH, GH, KE, LS, MW, MZ, NA, SD, SL, SZ, T2, UG, ZM, ZW, AM, AZ, BY, XO, KZ, MD, RU, TJ, TM			
PRIORITY APPLN. INFO.1			US 2005-656265P	P 20050224
			US 2005-691519P	P 20050617
			US 2005-725369P	P 20051011


OTHER SOURCE(S): MARPAT 145:293080
 GI




AB 2,4,5-Trisubstituted pyrimidine and bicyclic 2-aminopyrimidine derivs. I, wherein A is (un)substituted alkyl, halo, cyano, nitro, amine; B and C are (un)substituted NH, CH₂ or carbonyl; R1 is (un)substituted cycloalkyl or cycloalkenyl; R2 is (un)substituted Me, (un)substituted cycloalkyl, (un)substituted cycloalkenyl groups are prepared. Thus, II was prepared and displayed >90% inhibition in either GSK-3 α or GSK-3 β assay at

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 10 μ M. Due to their ability to modulate GSK-3 activity, I can be used as prodrugs in the treatment of CNS diseases, such as Alzheimer's disease and mood disorders, and metabolic diseases, such as insulin requiring states.


IT 908299-40-1P 908299-41-2P 908299-52-5P 908299-60-5P 908299-63-8P
 908299-66-1P 908299-69-4P 908299-71-8P
 908299-72-9P 908300-03-8P 908300-05-0P
 908300-11-8P 908300-13-0P 908300-19-6P
 908300-33-4P 908300-43-6P 908300-44-7P
 908300-48-1P 908300-49-2P 908300-70-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and GSK-3 modulation of 2,4,5-trisubstituted pyrimidine and bicyclic 2-aminopyrimidine derivs.)
 RN 908299-40-1 CAPLUS
 CN 6-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-phenyl- (9CI) (CA INDEX NAME)



RN 908299-41-2 CAPLUS
 CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-1,3-benzodioxol-5-yl-3-phenyl- (9CI) (CA INDEX NAME)




RN 908299-45-6 CAPLUS
 CN 1H-Isoindole-1,3(2H)-dione, 5-[(3-phenyl-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl)amino]- (9CI) (CA INDEX NAME)




RN 908299-52-5 CAPLUS


L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-1H-indazol-6-yl-3-phenyl- (9CI) (CA INDEX NAME)




RN 908299-60-5 CAPLUS
 CN 1(3H)-Isobenzofuranone, 5-[(3-(4-(1,1-dimethylethyl)phenyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl)amino]- (9CI) (CA INDEX NAME)




RN 908299-63-8 CAPLUS
 CN 1(3H)-Isobenzofuranone, 5-[(3-(2-methylphenyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl)amino]- (9CI) (CA INDEX NAME)




RN 908299-66-1 CAPLUS
 CN 1(3H)-Isobenzofuranone, 5-[(3-(2-methoxyphenyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl)amino]- (9CI) (CA INDEX NAME)




L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 908299-69-4 CAPLUS
 CN 1(3H)-Isobenzofuranone, 5-[(3-(2-chlorophenyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl)amino]- (9CI) (CA INDEX NAME)




RN 908299-71-8 CAPLUS
 CN 1(3H)-Isobenzofuranone, 5-[(3-(trifluoromethyl)phenyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl)amino]- (9CI) (CA INDEX NAME)




RN 908299-72-9 CAPLUS
 CN 1(3H)-Isobenzofuranone, 5-[(3-phenyl-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl)amino]- (9CI) (CA INDEX NAME)




RN 908300-03-8 CAPLUS
 CN 1H-Isoindol-1-one, 2,3-dihydro-5-[(3-(4-methylphenyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl)amino]- (9CI) (CA INDEX NAME)





RN 908300-05-0 CAPLUS
 CN 1H-Indol-1-one, 5-((3-(4-(1,1-dimethylethyl)phenyl)amino)-2,3-dihydro-1H-indol-1-one)- (9CI) (CA INDEX NAME)




RN 908300-11-8 CAPLUS
 CN 1H-Indol-1-one, 2,3-dihydro-5-((3-(1-methylethyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl)amino)- (9CI) (CA INDEX NAME)




RN 908300-13-0 CAPLUS
 CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, 3-(4-(1,1-dimethylethyl)phenyl)-N-[2-(trifluoromethyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 908300-49-2 CAPLUS
 CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, 3-(2,3-dihydro-1H-inden-5-yl)-N-1H-indol-6-yl- (9CI) (CA INDEX NAME)




RN 908300-70-9 CAPLUS
 CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-1H-benzotriazol-5-yl-3-phenyl- (9CI) (CA INDEX NAME)




RN 908301-54-2 CAPLUS
 CN 1(3H)-Isobenzofuranone, 6-((3-phenyl-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl)amino)- (9CI) (CA INDEX NAME)




RN 908300-19-6 CAPLUS
 CN 1(3H)-Isobenzofuranone, 5-((3-cyclopentyl-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl)amino)- (9CI) (CA INDEX NAME)




RN 908300-33-4 CAPLUS
 CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-1H-indazol-6-yl-3-tricyclo[3.3.1.13,7]dec-1-yl- (9CI) (CA INDEX NAME)




RN 908300-43-6 CAPLUS
 CN 1(3H)-Isobenzofuranone, 5-((3-(2,3-dihydro-1H-inden-5-yl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl)amino)- (9CI) (CA INDEX NAME)




RN 908300-44-7 CAPLUS
 CN 1H-Inden-1-one, 2,3-dihydro-5-((3-phenyl-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl)amino)- (9CI) (CA INDEX NAME)




RN 908300-48-1 CAPLUS
 CN 1H-Indole-1,3(2H)-dione, 5-((3-(2,3-dihydro-1H-inden-5-yl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl)amino)- (9CI) (CA INDEX NAME)




RN 908300-49-2 CAPLUS
 CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, 3-(2,3-dihydro-1H-inden-5-yl)-N-1H-indol-6-yl- (9CI) (CA INDEX NAME)




RN 908300-70-9 CAPLUS
 CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-1H-benzotriazol-5-yl-3-phenyl- (9CI) (CA INDEX NAME)




RN 908301-54-2 CAPLUS
 CN 1(3H)-Isobenzofuranone, 6-((3-phenyl-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl)amino)- (9CI) (CA INDEX NAME)







RN 840536-76-7 CAPLUS
 CN Benzoic acid, 2-(acetylamino)-5-[(3-[(3-(cyanomethyl)phenyl)amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 840536-77-8 CAPLUS
 CN Benzonitrile, 3-[(3-[(2-hydroxyethyl)phenyl]amino)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino)- (9CI) (CA INDEX NAME)




RN 840536-78-9 CAPLUS
 CN Benzenemethanol, 3-[5-[(4-(2-hydroxyethyl)phenyl)amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 840536-79-0 CAPLUS
 CN Benzenemethanol, 3-[(5-[(3-[(2-methoxyethoxy)phenyl]amino)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 840536-80-3 CAPLUS
 CN Methanesulfonamide, N-[3-[(3-[(cyanomethyl)phenyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 840536-81-4 CAPLUS
 CN Benzenesacetonitrile, 3-[(5-[(3-(methoxymethyl)phenyl)amino)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 840536-82-5 CAPLUS
 CN Benzenesacetonitrile, 3-[(5-[(4-(2-hydroxyethyl)phenyl)amino)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 840536-83-6 CAPLUS
 CN Carboxylic acid, [(3-[(5-[(4-fluorophenyl)amino)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]phenyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 840536-84-7 CAPLUS
 CN Benzenesacetamide, 3-[5-[(3-[(2-hydroxyethyl)amino]carbonyl)phenyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 840536-85-8 CAPLUS
 CN Benzenesacetamide, 3-[5-[(3-[(methylsulfonyl)amino]phenyl)amino)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 840536-86-9 CAPLUS
 CN Benzamide, 3-[(3-[(cyanomethyl)phenyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 840536-87-0 CAPLUS
 CN Benzenesacetonitrile, 3-[(5-[(3-(hydroxymethyl)phenyl)amino)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)



RN 840536-88-1 CAPLUS
 CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, 3-[(3-(aminomethyl)phenyl)-N-(4-fluorophenyl)-, dihydrochloride (9CI) (CA INDEX NAME)



• 2 HC1

IT 840536-89-2P 840536-90-5P 840536-91-6P

840536-92-7P 840536-94-9P 840536-95-0P

840536-96-1P 840536-97-2P 840536-98-3P

840536-99-4P 840537-00-0P 840537-01-1P

840537-02-2P 840537-03-3P 840537-04-4P

840537-05-5P 840537-06-6P 840537-08-8P

840537-09-9P 840537-10-2P 840537-11-3P

840537-12-4P 840537-13-5P 840537-14-6P

840537-15-7P 840537-16-8P 840537-17-9P

840537-18-0P 840537-19-1P 840537-20-4P

840537-21-5P 840537-22-6P 840537-23-7P

840537-24-8P 840537-25-9P 840537-26-0P

840537-27-1P 840537-28-2P 840537-29-3P

840537-30-6P 840537-31-7P 840537-32-8P

840537-33-9P 840537-34-0P 840537-35-1P

840537-36-2P 840537-37-3P 840537-38-4P

840537-39-5P 840537-40-6P 840537-79-3P,


840537-80-6P 840537-85-1P 840537-88-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of triazolopyrimidines as glycogen synthase kinase 3 inhibitors)


RN 840536-89-2 CAPLUS

CN Benzonitrile, 4-[(3-(3-(2-hydroxyethyl)phenyl)amino)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino- (9CI) (CA INDEX NAME)




RN 840536-90-5 CAPLUS

CN Benzenecarbonitrile, 3-[5-[(3-cyanophenyl)amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 840536-95-0 CAPLUS

CN Acetamide, N-[(3-[(4-fluorophenyl)amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl)phenyl]methyl- (9CI) (CA INDEX NAME)







RN 840536-96-1 CAPLUS

CN Benzonitrile, 4-[(3-[(2-methoxyethoxy)methyl]phenyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino- (9CI) (CA INDEX NAME)




RN 840536-97-2 CAPLUS

CN Benzenecarbonitrile, 4-[(4-fluorophenyl)amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl- (9CI) (CA INDEX NAME)

RN 840536-91-6 CAPLUS
CN Benzanamide, 4-[(3-(3-(cyanomethyl)phenyl)amino)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino- (9CI) (CA INDEX NAME)RN 840536-92-7 CAPLUS
CN Benzenecarbonitrile, 3-[(3-(2-hydroxyethyl)phenyl)amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl- (9CI) (CA INDEX NAME)RN 840536-94-9 CAPLUS
CN Benzenecarbonitrile, 3-[(3-(1-hydroxyethyl)phenyl)amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl- (9CI) (CA INDEX NAME)


RN 840536-95-0 CAPLUS

CN Acetamide, N-[(3-[(4-fluorophenyl)amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl)phenyl]methyl- (9CI) (CA INDEX NAME)






RN 840536-96-1 CAPLUS


CN Benzenecarbonitrile, 4-[(3-[(2-methoxyethoxy)methyl]phenyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl]amino- (9CI) (CA INDEX NAME)




RN 840536-97-2 CAPLUS

CN Benzenecarbonitrile, 4-[(4-fluorophenyl)amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl- (9CI) (CA INDEX NAME)


RN 840536-98-3 CAPLUS
CN Benzenecarbonitrile, 4-[(3-[(3-(2-methoxyethoxy)methyl]phenyl)amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl)phenyl]methyl- (9CI) (CA INDEX NAME)RN 840536-99-4 CAPLUS
CN Benzenecarbonitrile, 4-[(5-[(4-(2-hydroxyethyl)phenyl)amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl)phenyl]methyl- (9CI) (CA INDEX NAME)RN 840537-00-0 CAPLUS
CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-[(4-(aminomethyl)phenyl)-3-(3-fluorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




RN 840537-37-3 CAPLUS
 CN Benzamide, 4-[(3-[(3-(cyanomethyl)phenyl)amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl)amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 840537-38-4 CAPLUS
 CN Benzamide, 4-[(3-[(3-(methoxymethyl)phenyl)amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl)amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 840537-39-5 CAPLUS
 CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-(4-chlorophenyl)-3-[3-[(2-methoxyethoxy)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 840537-40-8 CAPLUS
 CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-(4-chlorophenyl)-3-[3-(methoxymethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 840537-79-3 CAPLUS
 CN Benzenesethanol, 3-[5-[(4-(2-aminoethyl)phenyl)amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 840537-80-6 CAPLUS
 CN Benzenesethanol, 3-[5-[[4-[(2,2,2-trifluoroethyl)amino]methyl]phenyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl- (9CI) (CA INDEX NAME)



RN 840537-85-1 CAPLUS
 CN Benzenecetonitrile, 3-[(4-aminomethyl)phenyl]amino-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl- (9CI) (CA INDEX NAME)



RN 840537-88-4 CAPLUS
 CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, 3-(3-fluorophenyl)-N-[(2,2,2-trifluoroethyl)amino]methyl-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2005122889 CAPLUS
 DOCUMENT NUMBER: 1421219304
 TITLE: Preparation of triazolopyrimidines as glycogen synthase kinase 3 inhibitors
 INVENTOR(S): Freyne, Eddy Jean Edgard; Love, Christopher John; Cocomans, Ludwig Paul; Vandermaesen, Nele; Buijntjers, Peter Jacobus Johanna Antonius; Willems, Marc; Embrechts, Werner Constant Johan; Janssen Pharmaceutica N.V., Belg.

PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.

SOURCE: PCT Int. Appl., 109 pp.


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012304	A2	20050210	WO 2004-EP51457	20040712
WO 2005012304	A3	20070426		
W: AE, AG, AL, AM, AT, AU, A2, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, T2, UA, UG, US, UZ, VC, VN, YU, ZA, 2M, ZW, RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, S2, T2, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, T3, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, EP, OA				
AU 2004260739	A1	20050210	AU 2004-260739	20040712
CA 2531232	A1	20050210	CA 2004-2531232	20040712
CH 1938308	A	20070328	CH 2004-80020418	20040712
EP 1781659	A2	20070509	EP 2004-766191	20040712
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, HR, LT, LV, MK				
US 2006163747	A1	20060817	US 2006-565065	20060117
PRIORITY APPLN. INFO.:			WO 2003-EP50314	A 20030716
			WO 2003-EP350314	A 20030716
			WO 2004-EP51457	W 20040712
OTHER SOURCE(S):			CASREACT 142:219304; HARPAT 142:219304	
GI				



I




II

AB The title compds. I [ring A = Ph, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl; R1 = H, aryl, formyl, etc.; X = a direct bond, (CH2)_n or (CH2)mX1aX1b (n = 1-4; m = 1-2; X1a = O, C(O), NR5; X1b = a direct bond, alkyl); R2 = cycloalkyl, Ph, 4-7 membered monocyclic heterocycle containing at least one heteroatom, selected from O, S or N, benzoxazolyl, etc.]; X2 = a direct bond, O, C(O), etc.; R3 = [un]substituted 5-6 membered monocyclic heterocycl or 9-10 membered bicyclic heterocycl, etc.; R4 = H, halo, OH, (un)substituted alkyl, etc.; R5 = H, alkyl, alkenyl, useful for the prevention or the treatment of diseases mediated through GSK3, were prepared E.g., a 4-step synthesis of II which showed pIC50 of > 8 against GSK3B and against GSX3a, was given. The pharmaceutical composition comprising the compound I is disclosed.

IT 842127-58-6P 842128-38-5P
 RN PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of triazolopyrimidines as glycogen synthase kinase 3 inhibitors)

RN 842127-58-6 CAPLUS

CN Acetamide, 2-methoxy-N-[(3-[5-[(3-oxazolyl)phenyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl)phenyl]methyl]- (9CI) (CA INDEX NAME)




842128-85-2P 842128-86-3P 842128-87-4P
 842128-88-5P 842128-89-6P 842128-90-9P
 842128-91-0P 842128-92-1P 842128-93-2P
 842128-94-3P 842128-95-4P 842128-96-5P
 842128-97-6P 842128-98-7P 842128-99-8P
 842129-00-4P 842129-01-5P 842129-27-5P
 842129-28-6P


RN PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of triazolopyrimidines as glycogen synthase kinase 3 inhibitors)

RN 842127-49-5 CAPLUS


CN 3H-1,2,4-Triazol-3-one, 5-[(3-[(3-(3-fluorophenyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl)amino]phenyl)-1,2-dihydro- (9CI) (CA INDEX NAME)




RN 842127-50-8 CAPLUS
 CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, 3-(3-bromophenyl)-N-(3-(2,5-dihydro-1H-imidazol-1-yl)phenyl)- (9CI) (CA INDEX NAME)



RN 842127-51-9 CAPLUS
 CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, 3-(3-bromophenyl)-N-[4-(1H-1,2,4-triazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 842128-38-5 CAPLUS
 CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, 3-(3-bromophenyl)-N-[3-(1-methyl-1H-pyrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)




IT 842127-49-5P 842127-50-8P 842127-51-9P
 842127-52-0P 842127-53-1P 842127-54-2P
 842127-55-3P 842127-56-4P 842127-57-5P
 842127-59-7P 842127-60-0P 842127-61-1P
 842127-62-2P 842127-63-3P 842127-64-4P
 842127-65-5P 842127-66-6P 842127-67-7P
 842127-68-8P 842127-69-9P 842127-70-2P
 842127-71-3P 842127-72-4P 842127-73-5P
 842127-74-6P 842127-75-7P 842127-76-8P
 842127-77-9P 842127-78-0P 842127-79-1P
 842127-80-4P 842127-81-5P 842127-82-6P
 842127-83-7P 842127-84-8P 842127-85-9P
 842127-86-0P 842127-87-1P 842127-88-2P
 842127-89-3P 842127-90-6P 842127-91-7P
 842127-92-8P 842127-93-9P 842127-94-0P
 842127-95-1P 842127-96-2P 842127-97-3P
 842127-98-4P 842127-99-5P 842128-00-1P
 842128-01-2P 842128-02-3P 842128-03-4P
 842128-04-5P 842128-05-6P 842128-06-7P
 842128-07-8P 842128-08-9P 842128-09-0P
 842128-10-3P 842128-11-4P 842128-13-6P
 842128-14-7P 842128-15-8P 842128-16-9P
 842128-17-0P 842128-18-1P 842128-19-2P
 842128-20-5P 842128-21-6P 842128-22-7P
 842128-23-8P 842128-24-9P 842128-25-0P
 842128-26-1P 842128-27-2P 842128-28-3P
 842128-29-4P 842128-30-7P 842128-31-8P
 842128-32-9P 842128-33-0P 842128-34-1P
 842128-35-2P 842128-36-3P 842128-37-4P
 842128-39-6P 842128-40-9P 842128-41-0P
 842128-42-1P 842128-43-2P 842128-44-3P
 842128-45-4P 842128-46-5P 842128-47-6P
 842128-48-7P 842128-49-8P 842128-50-1P
 842128-52-3P 842128-53-4P 842128-54-5P
 842128-55-6P 842128-56-7P 842128-57-8P
 842128-58-9P 842128-59-0P 842128-62-5P
 842128-63-6P 842128-64-7P 842128-65-8P
 842128-66-9P 842128-67-0P 842128-68-1P
 842128-69-2P 842128-70-5P 842128-71-6P
 842128-72-7P 842128-73-8P 842128-74-9P
 842128-75-0P 842128-76-1P 842128-77-2P
 842128-78-3P 842128-79-4P 842128-80-7P
 842128-81-0P 842128-83-0P 842128-84-1P


RN 842127-52-0 CAPLUS
 CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, 3-(3-fluorophenyl)-N-[3-(3-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 842127-53-1 CAPLUS
 CN Benzeneethanol, 3-[5-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl- (9CI) (CA INDEX NAME)




RN 842127-54-2 CAPLUS
 CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, 3-(3-fluorophenyl)-N-(3-pyridinylphenyl)- (9CI) (CA INDEX NAME)




RN 842127-55-3 CAPLUS
 CN Benzenecetonitrile, 3-[5-[(2-amino-4-pyrimidinyl)phenyl]amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl- (9CI) (CA INDEX NAME)




RN 842127-70-2 CAPLUS
 CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-ethyl-3-(3-fluorophenyl)-N-(3-(2-methyl-4-pyrimidinyl)phenyl)- (9CI) (CA INDEX NAME)




RN 842127-71-3 CAPLUS
 CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, 3-(3-fluorophenyl)-N-[3-(1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 842127-72-4 CAPLUS
 CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-[3-(1-methyl-1H-pyrazol-5-yl)phenyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 842127-73-5 CAPLUS
 CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, 3-[3-(aminomethyl)phenyl]-N-[3-(1-methyl-1H-pyrazol-5-yl)phenyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 842127-78-0 CAPLUS
 CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-[4-(4-morpholinyl)phenyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 842127-79-1 CAPLUS
 CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-[4-(4-methyl-1-piperazinyl)phenyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 842127-80-4 CAPLUS
 CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-[3-(1-methyl-1H-imidazol-2-yl)phenyl]-3-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 842127-81-5 CAPLUS
 CN Benzenethanol, 3-[5-[(3-(4-bromo-1-methyl-1H-pyrazol-3-yl)phenyl)amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)




RN 842127-74-6 CAPLUS
 CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-[3-(5-oxazolyl)phenyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 842127-75-7 CAPLUS
 CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-[3-(1-methyl-1H-tetrazol-5-yl)phenyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 842127-76-8 CAPLUS
 CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-[3-(2-amino-4-pyrimidinyl)phenyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 842127-77-9 CAPLUS
 CN 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, N-[4-(2-methyl-2H-tetrazol-5-yl)phenyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 842127-82-6 CAPLUS
 CN Benzenethanol, 3-[5-[(3-(1H-tetrazol-5-yl)phenyl)amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)



RN 842127-83-7 CAPLUS
 CN Benzenethanol, 3-[5-[(3-(1-methyl-1H-tetrazol-5-yl)phenyl)amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)



RN 842127-84-8 CAPLUS
 CN Benzenethanol, 3-[5-[(4-(4-methyl-1-piperazinyl)phenyl)amino]-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)